

**BILL SUMMARY**  
1<sup>st</sup> Session of the 52<sup>nd</sup> Legislature

<b>Bill No.:</b>	<b>SB 934</b>
<b>Version:</b>	<b>CS</b>
<b>Author:</b>	<b>Sen. Anderson/Rep. Schwartz</b>
<b>Date:</b>	<b>April 1, 2009</b>
<b>Impact:</b>	<b>\$0</b>

**Bill Summary**

**Fiscal Summary**

Fiscal Analyst: Mark Newman

The CS for SB 934 exempts antipsychotic medications from any Medicaid preferred drug list or any product-based prior authorization program, unless clinically recommended by the Drug Utilization Review Board and approved by the Chief Medical Officer of the Oklahoma Health Care Authority (OHCA) or when there is a generic equivalent drug available.

**Fiscal Analysis**

Based on estimates provided by OHCA, the CS for SB 934 will have no fiscal impact on appropriations or appropriated agencies. This legislation exempts drugs in this category for clinical purposes or when a generic equivalent is available. The recent development and marketing of specific generic antipsychotic medications will allow OHCA to realize additional savings based on drug rebates and discounts related to the use of preferred drugs.

**Long Term Fiscal Considerations**

None

Fiscal Analysis Reviewed By:

*Janice Buchanan*

House Fiscal Director